MYC and small cell lung carcinoma: While the association of MYC amplification with sensitivity to alisertib is not new observation [23, 28], we identify twice as many SCLC cell lines that are sensitive to alisertib based on high cMYC expression (14 cell lines) than would be identified by MYC amplification alone (7 cell lines).